Project Grant R01AG089497

Award Date 9/30/24
Completion Date 7/31/29
Dollars Obligated $2.8M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support Emory University's research into the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias. The $528,876 award, effective June 1, 2025, will fund the development of new analytic tools to integrate genomic data across multiple tissues and improve the identification of genetic risk factors and underlying molecular mechanisms for...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $784,596 to Northeastern University to conduct comprehensive and cell type-specific proteogenomic profiling of aberrant and mis-processed proteins in Alzheimer's disease (AD) and tauopathy models. The project aims to substantially expand understanding of protein dysfunctions in AD by applying state-of-the-art proteomic methods paired with proteogenomics across multiple brain regions, AD stages,...
This $107,948 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to enhance understanding of the biological signatures that distinguish subgroups of patients with Alzheimer's disease (AD). The key goals are to: Determine if AD subtypes can be identified solely using magnetic resonance imaging (MRI)-derived features through the application of machine learning algorithms. Integrate epigenetic profiles, including small non-coding RNA expression and DNA...
This Project Grant award of $328,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the Alzheimer's Disease Organelle Proteome Task (ADOPT) pilot phase. The interdisciplinary research team, led by Drs. Biao Wang and Danielle Swaney at the University of California, San Francisco, will use a genetic organelle tagging approach to rapidly purify lysosomes from neurons in wild-type and Alzheimer's disease mouse models. A suite of mass spectrometry experiments will then...
The National Institute on Aging (NIA), under its Aging Research Federal Grant Program (CFDA 93.866), awarded a $4,622,818 Cooperative Agreement to investigate proteomic biomarkers for cognitive and brain changes prior to the onset of Alzheimer's disease and related dementias (AD/ADRD). The project will measure 7,000 proteins and established AD/ADRD biomarkers in the Lothian Birth Cohort 1936, a well-characterized longitudinal study, at ages 73, 76, 82, and 85. The research aims to identify...
This $585,650 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund the "Alzheimer's Disease Big Data to Biology Training Program (ADBDB-TP)" at Emory University over a 5-year period from September 2024 to August 2029. The program aims to train a diverse cohort of 4 pre- and post-doctoral candidates annually to develop expertise in leveraging "big data" approaches to advance the understanding and treatment of Alzheimer's...
This $15,046,454 project grant from the National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research at the University of California, San Diego to improve understanding of proteomic changes preceding Alzheimer's disease and related dementias. The research will analyze longitudinal plasma samples from 2,836 women in the Women's Health Initiative Memory Study cohort using the Somamscan proteomics platform to identify novel...
This Project Grant award of $372,690 from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to discover the heterogeneous causal pathophysiology of Alzheimer's disease (AD). The project will develop new statistical methods to uncover how amyloid-beta, tau accumulation, and cognition are causally related in different AD subpopulations. The goal is to reveal optimal treatment windows and target groups for therapies that reduce amyloid-beta or...
This $6,226,692 project grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will support research to examine the role of neuronal hyperexcitability and proteostasis (protein homeostasis) in the development of Alzheimer's disease (AD). The primary focus is on investigating how modifications in brain activity, particularly in the locus coeruleus (LC) and hippocampus (HPC) regions, can lead to the key pathological hallmarks of AD....
This federal Project Grant award of $307,000.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to conduct a single, highly powered study to identify memory processes that are most sensitive to the asymptomatic, preclinical stage of Alzheimer's disease (AD) pathology. The study combines a continuous report item-location associative memory task with advanced behavioral and neural modeling to estimate subtle changes in memory precision that may differentiate healthy...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,840,883.00 to Emory University to conduct a proteomic comparison of sporadic early-onset, late-onset, and autosomal dominant Alzheimer's disease. The goal is to advance the understanding of the pathophysiology of sporadic early-onset Alzheimer's disease (SEOAD) and how it differs from late-onset Alzheimer's disease (LOAD) and autosomal dominant Alzheimer's disease (ADAD). The project will leverage a multi-platform discovery proteomic approach to analyze SEOAD and LOAD cerebrospinal fluid and plasma samples, with the aim of identifying brain-linked biomarkers that can predict cognitive decline. This research is expected to significantly increase the understanding of the protein network changes that characterize SEOAD and how they compare to LOAD and ADAD, which is critical for ensuring therapies and biomarkers developed for LOAD are applicable to early-onset forms of Alzheimer's disease.

Generated 7/1/25, 4:25 AM